9:58 AM
 | 
May 17, 2018
 |  BC Extra  |  Company News

Exelixis pockets $50M on Ipsen's first-line RCC approval

Ipsen Group (Euronext:IPN; Pink:IPSEY) said the European Commission approved an MAA for Cabometyx cabozantinib to treat first-line renal cell carcinoma, triggering a $50 million milestone payment to partner Exelixis Inc. (NASDAQ:EXEL)....

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >